Trends in Antiviral Drug Development

1. Auflage 2025
ISBN: 978-3-527-35301-9
Verlag: WILEY-VCH

Buch, Englisch, Band 3, 528 Seiten, Format (B × H): 170 mm x 244 mm

Reihe: Trends in Drug Discovery

Trends and challenges in one of the most active areas of contemporary drug development - presented by industry professionals with a track record of discovering new drugs and treatments.

Autoren/Hrsg.

Sofia, Michael J.

Wang, Zhengqiang

Weitere Mitwirkende

Fischer, János

Klein, Christian

Childers, Wayne E.

Rotella, David P.

Fachgebiete

• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Naturwissenschaften Biowissenschaften Mikrobiologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Medizinische Mikrobiologie & Virologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie

Inhaltsverzeichnis

Preface
Introduction: Successes and Challenges in Antiviral Drug Development

Part I: Human Herpes Viruses
Chapter 1: Letermovir
Chapter 2: Pritelivir

Part II: Immunodeficiency Virus
Chapter 3: Dolutegravir
Chapter 4: Islatravir (EFdA)

Part III: Hepatitis Viruses
Chapter 5: Imdusiran
Chapter 6: ARO-HBV/JNJ-3989
Chapter 7: Sofosbuvir
Chapter 8: Lidipasvir and Valpatasvir

Part IV: Respiratory Viruses
Chapter 9: Presatovir
Chapter 10: Remdesivir
Chapter 11: Ensitrelvir
Chapter 12: VV-116
Chapter 13: Molnupiravir

Part V: Tropical Disease Viruses
Chapter 14: Mosnodenvir

Part VI: Orthopoxvirus
Chapter 15: Brincidofovir

 

Über Autor(innen)

Michael J. Sofia, Ph.D. is the Co-founder and former Chief Scientific Officer of Arbutus Biopharma, Inc. where he established the programs in HBV-cure and coronaviruse therapeutics. During his career he has introduced numerous drugs into clinical development for both infectious diseases and inflammatory diseases, including the discovery and early development of sofosbuvir, which became the backbone of many HCV curative therapies. After graduating from the University of Illinois and spending time as an NIH research fellow, he held research and research management positions at Gilead Sciences, Pharmasset, Bristol-Myers Squibb, Transcell Technologies and Eli Lilly. He has received numerous awards for his work on hepatitis C including the 2015 ACS Heroes of Chemistry Award, 2016 IUPAC-Richter Prize, the 2016 Lasker-Debakey Award in Clinical Medical Research, and the 2017 Gertrude Elion Award.
 
Zhengqiang (ZQ) Wang, Ph.D. is Professor and Director of Chemistry at the Center for Drug Design, College of Pharmacy, University of Minnesota. He studied chemistry at Nankai University (China) and obtained his Ph.D. from Wayne State University (USA). He was a postdoc associate with Prof. Bob Vince, the inventor of HIV drug abacavir. As an independent researcher, he has led the medicinal chemistry of multiple sponsored antiviral drug discovery projects targeting important human viral pathogens, including HIV-1, HBV, HCMV and SARS-CoV-2.